<code id='F1CAEC10E7'></code><style id='F1CAEC10E7'></style>
    • <acronym id='F1CAEC10E7'></acronym>
      <center id='F1CAEC10E7'><center id='F1CAEC10E7'><tfoot id='F1CAEC10E7'></tfoot></center><abbr id='F1CAEC10E7'><dir id='F1CAEC10E7'><tfoot id='F1CAEC10E7'></tfoot><noframes id='F1CAEC10E7'>

    • <optgroup id='F1CAEC10E7'><strike id='F1CAEC10E7'><sup id='F1CAEC10E7'></sup></strike><code id='F1CAEC10E7'></code></optgroup>
        1. <b id='F1CAEC10E7'><label id='F1CAEC10E7'><select id='F1CAEC10E7'><dt id='F1CAEC10E7'><span id='F1CAEC10E7'></span></dt></select></label></b><u id='F1CAEC10E7'></u>
          <i id='F1CAEC10E7'><strike id='F1CAEC10E7'><tt id='F1CAEC10E7'><pre id='F1CAEC10E7'></pre></tt></strike></i>

          leisure time

          leisure time

          author:hotspot    Page View:984
          An light blue number 3 with an eye is surrounded by smaller, black number 3s on an orange background — 3 to watch coverage from STAT
          Christine Kao/STAT

          It’s been a slow year for medtech. Major deals in 2023 were scarce, funding was hard to come by, and valuations were down. On the policy side, the industry grappled with changing AI regulations, reimbursement woes, and device sterilization rules.

          Here are three political and market forces that shaped the medtech industry last year, and are worth paying attention to in 2024:

          advertisement

          Lobbying power of AI, software-enabled devices

          Medtech lobby AdvaMed announced earlier this month that the major medical imaging companies, previously housed within the National Electrical Manufacturers Association, were shifting to their shop. The device group also created a separate niche for digital health companies in October.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

          CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

          read more
          Diversifying clinical trials isn't enough to close racial gaps: study
          Diversifying clinical trials isn't enough to close racial gaps: study

          AdobeParticipationinaclinicaltrialisoftenconsideredsomethingofanequalizerinmedicine.Researchershavep

          read more
          Medicare details structure of new drug price negotiation program
          Medicare details structure of new drug price negotiation program

          MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

          read more

          Startling documents reveal new facets of Sacklers' opioid empire

          TheSacklernameadornsbuildingsandwingsofbuildingsatsomeoftheworld'stopuniversitiesandmuseums,likethis